Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Costimulatory Molecules and Immune Checkpoints Are Differentially Expressed on Different Subsets of Dendritic Cells.

Carenza C, Calcaterra F, Oriolo F, Di Vito C, Ubezio M, Della Porta MG, Mavilio D, Della Bella S.

Front Immunol. 2019 Jun 11;10:1325. doi: 10.3389/fimmu.2019.01325. eCollection 2019.

2.

Clinical characteristics and treatment outcome of an 86-year-old patient with acute myeloid leukaemia with acute promyelocytic-like morphology and uncommon RARA fusion variant.

Castelli R, Rossi V, Della Porta MG, Schiavon R, Barchiesi M, Cicconi L, Coco FL.

Ann Hematol. 2018 Dec;97(12):2523-2525. doi: 10.1007/s00277-018-3377-7. Epub 2018 Jun 5. No abstract available.

PMID:
29872883
3.

Multicenter validation of a simplified method for paroxysmal nocturnal hemoglobinuria screening.

Gatti A, Del Vecchio L, Geuna M, Della Porta MG, Brando B.

Eur J Haematol. 2017 Jul;99(1):27-35. doi: 10.1111/ejh.12885. Epub 2017 Apr 17.

PMID:
28332730
4.

Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System.

Della Porta MG, Jackson CH, Alessandrino EP, Rossi M, Bacigalupo A, van Lint MT, Bernardi M, Allione B, Bosi A, Guidi S, Santini V, Malcovati L, Ubezio M, Milanesi C, Todisco E, Voso MT, Musto P, Onida F, Iori AP, Cerretti R, Grillo G, Molteni A, Pioltelli P, Borin L, Angelucci E, Oldani E, Sica S, Pascutto C, Ferretti V, Santoro A, Bonifazi F, Cazzola M, Rambaldi A.

Leukemia. 2017 Nov;31(11):2449-2457. doi: 10.1038/leu.2017.88. Epub 2017 Mar 21.

5.

Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes.

Della Porta MG, Picone C.

Mediterr J Hematol Infect Dis. 2017 Feb 15;9(1):e2017017. doi: 10.4084/MJHID.2017.017. eCollection 2017. Review.

6.

Breast and renal cancer-Derived endothelial colony forming cells share a common gene signature.

Moccia F, Fotia V, Tancredi R, Della Porta MG, Rosti V, Bonetti E, Poletto V, Marchini S, Beltrame L, Gallizzi G, Da Prada GA, Pedrazzoli P, Riccardi A, Porta C, Zambelli A, D'Incalci M.

Eur J Cancer. 2017 May;77:155-164. doi: 10.1016/j.ejca.2017.01.025. Epub 2017 Feb 28.

PMID:
28258798
7.

Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms.

Romano M, Della Porta MG, Gallì A, Panini N, Licandro SA, Bello E, Craparotta I, Rosti V, Bonetti E, Tancredi R, Rossi M, Mannarino L, Marchini S, Porcu L, Galmarini CM, Zambelli A, Zecca M, Locatelli F, Cazzola M, Biondi A, Rambaldi A, Allavena P, Erba E, D'Incalci M.

Br J Cancer. 2017 Jan;116(3):335-343. doi: 10.1038/bjc.2016.424. Epub 2017 Jan 10.

8.

Vascular endothelial growth factor overexpression in myelodysplastic syndrome bone marrow cells: biological and clinical implications.

Invernizzi R, Travaglino E, Della Porta MG, Malcovati L, Gallì A, Bastia R, Ciola M, Ambaglio I, Boveri E, Rosti V, Cazzola M.

Leuk Lymphoma. 2017 Jul;58(7):1711-1720. doi: 10.1080/10428194.2016.1262030. Epub 2016 Nov 29.

PMID:
27897450
9.

Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group.

Westers TM, Cremers EM, Oelschlaegel U, Johansson U, Bettelheim P, Matarraz S, Orfao A, Moshaver B, Brodersen LE, Loken MR, Wells DA, Subirá D, Cullen M, Te Marvelde JG, van der Velden VH, Preijers FW, Chu SC, Feuillard J, Guérin E, Psarra K, Porwit A, Saft L, Ireland R, Milne T, Béné MC, Witte BI, Della Porta MG, Kern W, van de Loosdrecht AA; IMDSFlow Working Group.

Haematologica. 2017 Feb;102(2):308-319. doi: 10.3324/haematol.2016.147835. Epub 2016 Oct 6.

10.

Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation.

Della Porta MG, Gallì A, Bacigalupo A, Zibellini S, Bernardi M, Rizzo E, Allione B, van Lint MT, Pioltelli P, Marenco P, Bosi A, Voso MT, Sica S, Cuzzola M, Angelucci E, Rossi M, Ubezio M, Malovini A, Limongelli I, Ferretti VV, Spinelli O, Tresoldi C, Pozzi S, Luchetti S, Pezzetti L, Catricalà S, Milanesi C, Riva A, Bruno B, Ciceri F, Bonifazi F, Bellazzi R, Papaemmanuil E, Santoro A, Alessandrino EP, Rambaldi A, Cazzola M.

J Clin Oncol. 2016 Oct 20;34(30):3627-3637. doi: 10.1200/JCO.2016.67.3616.

11.

Prognostic models in myelodysplastic syndromes.

Della Porta MG.

Lancet Haematol. 2015 Jun;2(6):e229-30. doi: 10.1016/S2352-3026(15)00110-6. Epub 2015 Jun 3. No abstract available.

PMID:
26688232
12.

SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts.

Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, Jädersten M, Jansson M, Elena C, Gallì A, Walldin G, Della Porta MG, Raaschou-Jensen K, Travaglino E, Kallenbach K, Pietra D, Ljungström V, Conte S, Boveri E, Invernizzi R, Rosenquist R, Campbell PJ, Cazzola M, Hellström Lindberg E.

Blood. 2015 Jul 9;126(2):233-41. doi: 10.1182/blood-2015-03-633537. Epub 2015 May 8.

13.

Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM).

Della Porta MG, Tuechler H, Malcovati L, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SM, Miyazaki Y, Pfeilstöcker M, Sekeres MA, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D, Greenberg PL, Cazzola M.

Leukemia. 2015 Jul;29(7):1502-13. doi: 10.1038/leu.2015.55. Epub 2015 Feb 27.

PMID:
25721895
14.

Pretransplantation therapy with hypomethylating agents in patients with myelodysplastic syndromes receiving reduced-intensity conditioning regimens.

Della Porta MG, Alessandrino EP.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1260-1. doi: 10.1016/j.bbmt.2014.07.006. Epub 2014 Jul 11. No abstract available.

15.

Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia.

Malcovati L, Papaemmanuil E, Ambaglio I, Elena C, Gallì A, Della Porta MG, Travaglino E, Pietra D, Pascutto C, Ubezio M, Bono E, Da Vià MC, Brisci A, Bruno F, Cremonesi L, Ferrari M, Boveri E, Invernizzi R, Campbell PJ, Cazzola M.

Blood. 2014 Aug 28;124(9):1513-21. doi: 10.1182/blood-2014-03-560227. Epub 2014 Jun 26.

16.

Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes.

Della Porta MG, Travaglino E, Boveri E, Ponzoni M, Malcovati L, Papaemmanuil E, Rigolin GM, Pascutto C, Croci G, Gianelli U, Milani R, Ambaglio I, Elena C, Ubezio M, Da Via' MC, Bono E, Pietra D, Quaglia F, Bastia R, Ferretti V, Cuneo A, Morra E, Campbell PJ, Orazi A, Invernizzi R, Cazzola M; Rete Ematologica Lombarda (REL) Clinical Network.

Leukemia. 2015 Jan;29(1):66-75. doi: 10.1038/leu.2014.161. Epub 2014 May 20.

PMID:
24935723
17.

Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS.

Porwit A, van de Loosdrecht AA, Bettelheim P, Brodersen LE, Burbury K, Cremers E, Della Porta MG, Ireland R, Johansson U, Matarraz S, Ogata K, Orfao A, Preijers F, Psarra K, Subirá D, Valent P, van der Velden VH, Wells D, Westers TM, Kern W, Béné MC.

Leukemia. 2014 Sep;28(9):1793-8. doi: 10.1038/leu.2014.191. Epub 2014 Jun 12.

PMID:
24919805
18.

Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R.

Della Porta MG, Alessandrino EP, Bacigalupo A, van Lint MT, Malcovati L, Pascutto C, Falda M, Bernardi M, Onida F, Guidi S, Iori AP, Cerretti R, Marenco P, Pioltelli P, Angelucci E, Oneto R, Ripamonti F, Bernasconi P, Bosi A, Cazzola M, Rambaldi A; Gruppo Italiano Trapianto di Midollo Osseo.

Blood. 2014 Apr 10;123(15):2333-42. doi: 10.1182/blood-2013-12-542720. Epub 2014 Feb 20.

19.

Prognostic significance of reproducible immunophenotypic markers of marrow dysplasia.

Della Porta MG, Picone C, Tenore A, Yokose N, Malcovati L, Cazzola M, Ogata K.

Haematologica. 2014 Jan;99(1):e8-10. doi: 10.3324/haematol.2013.097188. No abstract available.

20.

Complex patterns of chromosome 11 aberrations in myeloid malignancies target CBL, MLL, DDB1 and LMO2.

Klampfl T, Milosevic JD, Puda A, Schönegger A, Bagienski K, Berg T, Harutyunyan AS, Gisslinger B, Rumi E, Malcovati L, Pietra D, Elena C, Della Porta MG, Pieri L, Guglielmelli P, Bock C, Doubek M, Dvorakova D, Suvajdzic N, Tomin D, Tosic N, Racil Z, Steurer M, Pavlovic S, Vannucchi AM, Cazzola M, Gisslinger H, Kralovics R.

PLoS One. 2013 Oct 16;8(10):e77819. doi: 10.1371/journal.pone.0077819. eCollection 2013.

21.

The genetic basis of myelodysplasia and its clinical relevance.

Cazzola M, Della Porta MG, Malcovati L.

Blood. 2013 Dec 12;122(25):4021-34. doi: 10.1182/blood-2013-09-381665. Epub 2013 Oct 17. Review.

22.

Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, Yoon CJ, Ellis P, Wedge DC, Pellagatti A, Shlien A, Groves MJ, Forbes SA, Raine K, Hinton J, Mudie LJ, McLaren S, Hardy C, Latimer C, Della Porta MG, O'Meara S, Ambaglio I, Galli A, Butler AP, Walldin G, Teague JW, Quek L, Sternberg A, Gambacorti-Passerini C, Cross NC, Green AR, Boultwood J, Vyas P, Hellstrom-Lindberg E, Bowen D, Cazzola M, Stratton MR, Campbell PJ; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium.

Blood. 2013 Nov 21;122(22):3616-27; quiz 3699. doi: 10.1182/blood-2013-08-518886. Epub 2013 Sep 12.

23.

Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes.

Pellagatti A, Benner A, Mills KI, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG, Jädersten M, Verma A, McDonald EJ, Killick S, Hellström-Lindberg E, Bullinger L, Wainscoat JS, Boultwood J.

J Clin Oncol. 2013 Oct 1;31(28):3557-64. doi: 10.1200/JCO.2012.45.5626. Epub 2013 Sep 3.

PMID:
24002510
24.

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet.

Malcovati L, Hellström-Lindberg E, Bowen D, Adès L, Cermak J, Del Cañizo C, Della Porta MG, Fenaux P, Gattermann N, Germing U, Jansen JH, Mittelman M, Mufti G, Platzbecker U, Sanz GF, Selleslag D, Skov-Holm M, Stauder R, Symeonidis A, van de Loosdrecht AA, de Witte T, Cazzola M; European Leukemia Net.

Blood. 2013 Oct 24;122(17):2943-64. doi: 10.1182/blood-2013-03-492884. Epub 2013 Aug 26.

25.

Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome?

Alessandrino EP, Della Porta MG, Pascutto C, Bacigalupo A, Rambaldi A.

J Clin Oncol. 2013 Jul 20;31(21):2761-2. doi: 10.1200/JCO.2012.48.0525. Epub 2013 Jun 17. No abstract available.

PMID:
23775971
26.

Prognosis of secondary acute myeloid leukemia.

Della Porta MG.

Leuk Res. 2013 Aug;37(8):857-8. doi: 10.1016/j.leukres.2013.04.016. Epub 2013 May 10. No abstract available.

PMID:
23664172
27.

Effects of mitochondrial ferritin overexpression in normal and sideroblastic erythroid progenitors.

Invernizzi R, Travaglino E, Della Porta MG, Gallì A, Malcovati L, Rosti V, Bergamaschi G, Erba BG, Bellistri F, Bastia R, Santambrogio P, Levi S, Cazzola M.

Br J Haematol. 2013 Jun;161(5):726-37. doi: 10.1111/bjh.12316. Epub 2013 Apr 10.

PMID:
23573868
28.

Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia.

Such E, Germing U, Malcovati L, Cervera J, Kuendgen A, Della Porta MG, Nomdedeu B, Arenillas L, Luño E, Xicoy B, Amigo ML, Valcarcel D, Nachtkamp K, Ambaglio I, Hildebrandt B, Lorenzo I, Cazzola M, Sanz G.

Blood. 2013 Apr 11;121(15):3005-15. doi: 10.1182/blood-2012-08-452938. Epub 2013 Jan 31.

29.

Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1.

Ambaglio I, Malcovati L, Papaemmanuil E, Laarakkers CM, Della Porta MG, Gallì A, Da Vià MC, Bono E, Ubezio M, Travaglino E, Albertini R, Campbell PJ, Swinkels DW, Cazzola M.

Haematologica. 2013 Mar;98(3):420-3. doi: 10.3324/haematol.2012.077446. Epub 2013 Jan 8.

30.

Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group.

van de Loosdrecht AA, Ireland R, Kern W, Della Porta MG, Alhan C, Balleisen JS, Bettelheim P, Bowen DT, Burbury K, Eidenschink L, Cazzola M, Chu SS, Cullen M, Cutler JA, Dräger AM, Feuillard J, Fenaux P, Font P, Germing U, Haase D, Hellström-Lindberg E, Johansson U, Kordasti S, Loken MR, Malcovati L, te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Nikolova V, Ogata K, Oelschlaegel U, Orfao A, Ossenkoppele GJ, Porwit A, Platzbecker U, Preijers F, Psarra K, Richards SJ, Subirá D, Seymour JF, Tindell V, Vallespi T, Valent P, van der Velden VH, Wells DA, de Witte TM, Zettl F, Béné MC, Westers TM.

Leuk Lymphoma. 2013 Mar;54(3):472-5. doi: 10.3109/10428194.2012.718341. Epub 2012 Sep 14. Review.

PMID:
22916713
31.

Improving the prognostic assessment of myelodysplastic syndromes by understanding the biology of the disease.

Della Porta MG.

Leuk Res. 2012 Oct;36(10):1225-6. doi: 10.1016/j.leukres.2012.06.013. Epub 2012 Jul 19. No abstract available.

PMID:
22819073
32.

Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study.

Della Porta MG, Picone C, Pascutto C, Malcovati L, Tamura H, Handa H, Czader M, Freeman S, Vyas P, Porwit A, Saft L, Westers TM, Alhan C, Cali C, van de Loosdrecht AA, Ogata K.

Haematologica. 2012 Aug;97(8):1209-17. doi: 10.3324/haematol.2011.048421. Epub 2012 Feb 7.

33.

Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group.

Westers TM, Ireland R, Kern W, Alhan C, Balleisen JS, Bettelheim P, Burbury K, Cullen M, Cutler JA, Della Porta MG, Dräger AM, Feuillard J, Font P, Germing U, Haase D, Johansson U, Kordasti S, Loken MR, Malcovati L, te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Ogata K, Orfao A, Porwit A, Psarra K, Richards SJ, Subirá D, Tindell V, Vallespi T, Valent P, van der Velden VH, de Witte TM, Wells DA, Zettl F, Béné MC, van de Loosdrecht AA.

Leukemia. 2012 Jul;26(7):1730-41. doi: 10.1038/leu.2012.30. Epub 2012 Feb 6.

PMID:
22307178
34.

Clinical evaluation of extra-hematologic comorbidity in myelodysplastic syndromes: ready-to-wear versus made-to-measure tool.

Della Porta MG, Ambaglio I, Ubezio M, Travaglino E, Pascutto C, Malcovati L.

Haematologica. 2012 Apr;97(4):631-2. doi: 10.3324/haematol.2011.057323. Epub 2012 Jan 22. No abstract available.

35.

Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.

Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C, Travaglino E, Groves MJ, Godfrey AL, Ambaglio I, Gallì A, Da Vià MC, Conte S, Tauro S, Keenan N, Hyslop A, Hinton J, Mudie LJ, Wainscoat JS, Futreal PA, Stratton MR, Campbell PJ, Hellström-Lindberg E, Cazzola M; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium and of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative.

Blood. 2011 Dec 8;118(24):6239-46. doi: 10.1182/blood-2011-09-377275. Epub 2011 Oct 12.

36.

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.

Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, Pellagatti A, Wainscoat JS, Hellstrom-Lindberg E, Gambacorti-Passerini C, Godfrey AL, Rapado I, Cvejic A, Rance R, McGee C, Ellis P, Mudie LJ, Stephens PJ, McLaren S, Massie CE, Tarpey PS, Varela I, Nik-Zainal S, Davies HR, Shlien A, Jones D, Raine K, Hinton J, Butler AP, Teague JW, Baxter EJ, Score J, Galli A, Della Porta MG, Travaglino E, Groves M, Tauro S, Munshi NC, Anderson KC, El-Naggar A, Fischer A, Mustonen V, Warren AJ, Cross NC, Green AR, Futreal PA, Stratton MR, Campbell PJ; Chronic Myeloid Disorders Working Group of the International Cancer Genome Consortium.

N Engl J Med. 2011 Oct 13;365(15):1384-95. doi: 10.1056/NEJMoa1103283. Epub 2011 Sep 26.

37.

Classification and prognostic evaluation of myelodysplastic syndromes.

Cazzola M, Della Porta MG, Travaglino E, Malcovati L.

Semin Oncol. 2011 Oct;38(5):627-34. doi: 10.1053/j.seminoncol.2011.04.007. Review.

PMID:
21943669
38.

Myelodysplastic syndromes and bone marrow microenvironment.

Della Porta MG.

Leuk Res. 2011 Nov;35(11):1442-3. doi: 10.1016/j.leukres.2011.07.035. Epub 2011 Aug 26. No abstract available.

PMID:
21872330
39.

Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms.

Elena C, Rumi E, Portolan M, Della Porta MG, Pascutto C, Passamonti F.

Haematologica. 2011 Aug;96(8):1236-8. doi: 10.3324/haematol.2011.047803. No abstract available.

40.

Over-expression of mitochondrial ferritin affects the JAK2/STAT5 pathway in K562 cells and causes mitochondrial iron accumulation.

Santambrogio P, Erba BG, Campanella A, Cozzi A, Causarano V, Cremonesi L, Gallì A, Della Porta MG, Invernizzi R, Levi S.

Haematologica. 2011 Oct;96(10):1424-32. doi: 10.3324/haematol.2011.042952. Epub 2011 Jun 28.

41.

Flow cytometry immunophenotyping for the evaluation of bone marrow dysplasia.

Della Porta MG, Lanza F, Del Vecchio L; Italian Society of Cytometry (GIC).

Cytometry B Clin Cytom. 2011 Jul-Aug;80(4):201-11. doi: 10.1002/cyto.b.20607. Epub 2011 Jun 14. Review.

42.

Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS).

Malcovati L, Della Porta MG, Strupp C, Ambaglio I, Kuendgen A, Nachtkamp K, Travaglino E, Invernizzi R, Pascutto C, Lazzarino M, Germing U, Cazzola M.

Haematologica. 2011 Oct;96(10):1433-40. doi: 10.3324/haematol.2011.044602. Epub 2011 Jun 9.

43.

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome.

Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG, Jädersten M, Killick S, Vyas P, Hellström-Lindberg E, Wainscoat JS, Boultwood J.

Br J Haematol. 2011 Oct;155(2):272-4. doi: 10.1111/j.1365-2141.2011.08672.x. Epub 2011 Apr 15. No abstract available.

PMID:
21492127
44.

Myelodysplastic syndromes with bone marrow fibrosis.

Della Porta MG, Malcovati L.

Haematologica. 2011 Feb;96(2):180-3. doi: 10.3324/haematol.2010.039875. No abstract available.

45.

Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors.

Mariucci S, Rovati B, Manzoni M, Della Porta MG, Comolli G, Delfanti S, Danova M.

Clin Exp Med. 2011 Dec;11(4):199-210. doi: 10.1007/s10238-010-0120-7. Epub 2010 Dec 16. Review.

PMID:
21161672
46.

Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.

Zambelli A, Della Porta MG, Eleuteri E, De Giuli L, Catalano O, Tondini C, Riccardi A.

Breast. 2011 Apr;20(2):176-83. doi: 10.1016/j.breast.2010.11.002. Epub 2010 Dec 13. Review.

PMID:
21146409
47.

Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome.

Della Porta MG, Malcovati L, Strupp C, Ambaglio I, Kuendgen A, Zipperer E, Travaglino E, Invernizzi R, Pascutto C, Lazzarino M, Germing U, Cazzola M.

Haematologica. 2011 Mar;96(3):441-9. doi: 10.3324/haematol.2010.033506. Epub 2010 Dec 6.

48.

Burkitt-like lymphoma infiltrating a hyperfunctioning thyroid adenoma and presenting as a hot nodule.

Camera A, Magri F, Fonte R, Villani L, Della Porta MG, Fregoni V, Manna LL, Chiovato L.

Thyroid. 2010 Sep;20(9):1033-6. doi: 10.1089/thy.2010.0048.

PMID:
20825299
49.

Treatment of anemia with erythroid stimulating agents in myelodysplastic syndromes.

Della Porta MG.

Leuk Res. 2011 Jan;35(1):22-3. doi: 10.1016/j.leukres.2010.07.033. Epub 2010 Aug 19. No abstract available.

PMID:
20727588
50.

Flow cytometric analysis of peripheral blood dendritic cells in patients with severe sepsis.

Riccardi F, Della Porta MG, Rovati B, Casazza A, Radolovich D, De Amici M, Danova M, Langer M.

Cytometry B Clin Cytom. 2011 Jan;80(1):14-21. doi: 10.1002/cyto.b.20540.

Supplemental Content

Loading ...
Support Center